| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS30086012 | HIV | ENSG00000188778.6 | protein_coding | ADRB3 | No | No | 155 | A8KAG8 P13945 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | ADRB3 |
|---|---|
| DrugBank ID | DB04861 |
| Drug Name | Nebivolol |
| Target ID | BE0001012 |
| UniProt ID | P13945 |
| Regulation Type | agonist |
| PubMed IDs | 16961165; 26177892; 1968323; 2455841; 28509722 |
| Citations | Gielen W, Cleophas TJ, Agrawal R: Nebivolol: a review of its clinical and pharmacological characteristics. Int J Clin Pharmacol Ther. 2006 Aug;44(8):344-57.@@Fongemie J, Felix-Getzik E: A Review of Nebivolol Pharmacology and Clinical Evidence. Drugs. 2015 Aug;75(12):1349-71. doi: 10.1007/s40265-015-0435-5.@@De Cree J, Cobo C, Geukens H, Verhaegen H: Comparison of the subacute hemodynamic effects of atenolol, propranolol, pindolol, and nebivolol. Angiology. 1990 Feb;41(2):95-105. doi: 10.1177/000331979004100202.@@Van de Water A, Janssens W, Van Neuten J, Xhonneux R, De Cree J, Verhaegen H, Reneman RS, Janssen PA: Pharmacological and hemodynamic profile of nebivolol, a chemically novel, potent, and selective beta 1-adrenergic antagonist. J Cardiovasc Pharmacol. 1988 May;11(5):552-63. doi: 10.1097/00005344-198805000-00007.@@Giles TD, Cockcroft JR, Pitt B, Jakate A, Wright HM: Rationale for nebivolol/valsartan combination for hypertension: review of preclinical and clinical data. J Hypertens. 2017 Sep;35(9):1758-1767. doi: 10.1097/HJH.0000000000001412. |
| Groups | Approved; Investigational |
| Direct Classification | 1-benzopyrans |
| SMILES | OC(CNCC(O)C1CCC2=C(O1)C=CC(F)=C2)C1CCC2=C(O1)C=CC(F)=C2 |
| Pathways | Nebivolol Action Pathway |
| PharmGKB | PA151958426 |
| ChEMBL | CHEMBL434394 |
